---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-239304"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2021-08-06T23:59:59+00:00"
generated_at: "2026-06-29T20:53:59.263670+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics VP Finance Resigns; Controller Appointed Interim Principal Accounting Officer

## Summary
- Justin Thacker resigned as VP Finance and principal accounting officer effective August 13, 2021.
- Dawn Giangiulio, Controller since April 2020, appointed interim principal accounting officer effective August 13, 2021.
- Giangiulio also serves as Controller of ARS Pharmaceuticals on a part-time basis, resigning September 3, 2021.
- Previously, Giangiulio was Senior Manager R&D Finance at Teva Pharmaceutical Industries from 2015 to 2020.
- Giangiulio is a licensed CPA and began her career at PricewaterhouseCoopers.

## SEC filing metadata
- accession: 0001193125-21-239304
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2021-08-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/d203283d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-239304
- JSON: https://secwatch.observer/filing/0001193125-21-239304.json
- Plain text: https://secwatch.observer/filing/0001193125-21-239304.txt

## Key facts
- Executive change
  Justin Thacker resigned as VP, Finance at Design Therapeutics, Inc..
  - Action: resigned
  - Role: VP, Finance
  source text: On August 2, 2021, Justin Thacker notified Design Therapeutics, Inc. (the “Company”) of his intention to resign as the Company’s VP, Finance and from his position as the Company’s principal accounting officer, effective August 13, 2021, to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm
- Executive change
  Dawn Giangiulio was appointed as interim principal accounting officer at Design Therapeutics, Inc..
  - Action: appointed
  - Role: interim principal accounting officer
  source text: Effective as of August 13, 2021, Dawn Giangiulio, the Company’s Controller, will become the Company’s interim principal accounting officer for purposes of the Securities Exchange Act of 1934, as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000119312521239304/0001193125-21-239304-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.